Myocardial Infarction News and Research

RSS

Endothelial cells can function as cardiac stem cells to produce new heart muscle tissue

Endothelial cells residing in the coronary arteries can function as cardiac stem cells to produce new heart muscle tissue, Vanderbilt University investigators have discovered.

21 Aug 2014

Study could pave way for preventing brain and cardiac ischemia induced by atherosclerosis

A recent Finnish study could pave the way for preventing brain and cardiac ischemia induced by atherosclerosis. Finnish researchers have found that the low-expression variant of fatty acid-binding protein 4 (FABP4), which is particularly common among Finns, reduces the risk of heart attack and stroke.

21 Aug 2014

Experts open new clinic to evaluate heart disease patients for participation in stem cell studies

Regenerative medicine experts at the Cedars-Sinai Heart Institute have opened a new clinic to evaluate heart and vascular disease patients for participation in stem cell medical studies.

13 Aug 2014

Scientists identify long-overlooked function of vascular smooth muscle cells in atherosclerosis

Scientists at the Interfaculty Institute of Biochemistry (IFIB) have collaborated with colleagues from the Department of Pharmacy and the Department of Dermatology of the University of Tübingen to identify a long-overlooked function of vascular smooth muscle cells in atherosclerosis.

12 Aug 2014

Improving care, outcomes for NSTEMI patients linked to higher survival rates

Changes in the treatment of the most common form of heart attack over the past decade have been associated with higher survival rates for men and women regardless of age, race and ethnicity, according to a UCLA-led analysis.

5 Aug 2014

Regeneron announces FDA approval of EYLEA Injection for DME treatment

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME).

31 Jul 2014

EMA CHMP issues positive opinion for label updates to Takeda's Vipidia, Vipdomet and Incresync

Takeda Pharmaceuticals International GmbH today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued positive opinions for updates to the Summary of Product Characteristics (SmPC) for Vipidia (alogliptin) and the fixed-dose combination (FDC) therapies Vipdomet (alogliptin and metformin) and Incresync (alogliptin and pioglitazone).

30 Jul 2014

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME).

29 Jul 2014

University of Leicester receives funding from two Masonic charities for heart study

A University of Leicester research project has received vital philanthropic funding for the second year from two Masonic charities.

23 Jul 2014

BP variability may be ‘CV risk integrator’

Increased variability in blood pressure may be an indicator of overall cardiovascular risk rather than being a risk factor per se, suggest researchers.

21 Jul 2014

IL-10 enhances positive benefits of transplanted allogenic SMCs to repair cardiac tissues after MI

The long-term, positive benefits of transplanted allogenic (other-donated) smooth muscle cells (SMCs) to repair cardiac tissues after myocardial infarction (MI) have been enhanced by the addition of interleukin 10 (IL-10) to the transplanted cells, report researchers in Canada.

21 Jul 2014

Common genetic variation in gene may modify cardiovascular benefit of aspirin

Aspirin is the gold standard for antiplatelet therapy and a daily low-dose aspirin is widely prescribed for the prevention of cardiovascular disease.

21 Jul 2014

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Regeneron Pharmaceuticals, Inc. today announced that in the Phase 3 VIVID-DME trial of EYLEA® (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser photocoagulation.

18 Jul 2014

Pain control in osteoarthritis patients

Osteoarthritis (OA) is one of the most common causes of disability, and inadequate pain control can lead to joint stiffness that may impair mobility for patients.

9 Jul 2014

Findings shed light on possible role of affective temperaments in cardiovascular morbidity

Temperament has been traditionally associated with high blood pressure. A new study that has appeared in the current issue of Psychotherapy and Psychosomatics has substantiated this issue.

7 Jul 2014

Pneumonia patients treated with azithromycin face lower risk of death, slightly increased risk of heart attack

In a study that included nearly 65,000 older patients hospitalized with pneumonia, treatment that included azithromycin compared with other antibiotics was associated with a significantly lower risk of death and a slightly increased risk of heart attack, according to a study in the June 4 issue of JAMA.

4 Jul 2014

Study demonstrates cost-effectiveness of Ottawa Model for Smoking Cessation

In a recent study published in Tobacco Control, researchers at the University of Ottawa Heart Institute have demonstrated the cost-effectiveness of the Ottawa Model for Smoking Cessation (OMSC), an intervention that includes in-hospital counseling, pharmacotherapy and post-hospital follow-up, compared to usual care among smokers hospitalized with acute myocardial infarction, unstable angina, heart failure, and chronic obstructive pulmonary disease.

19 Jun 2014

Counseling, medication management by pharmacist can lower hospital readmissions

Getting discharged from the hospital and then having to go right back in again can be emotionally draining for a patient and their family. It can also cause financial strain for all involved - the patient, the hospital system and the insurers-including Medicaid and Medicare, which are taxpayer funded.

19 Jun 2014

Genetic variants linked to race that explains risk of death among patients taking Plavix after heart attack

Researchers have identified the first genetic variations linked to race that begin to explain a higher risk of death among some African American and Caucasian patients taking the anti-clotting drug clopidogrel (Plavix) after a heart attack.

18 Jun 2014

Recreational football training sessions lower blood pressure and improves heart function

The studies, published in the acclaimed Scandinavian Journal of Medicine & Science in Sports, show that 24 weeks of twice-weekly recreational football training sessions lower blood pressure and improves heart function in men with high blood pressure and men with type 2 diabetes.

13 Jun 2014

Myocardial Infarction News and Research

Endothelial cells can function as cardiac stem cells to produce new heart muscle tissue

Study could pave way for preventing brain and cardiac ischemia induced by atherosclerosis

Experts open new clinic to evaluate heart disease patients for participation in stem cell studies

Scientists identify long-overlooked function of vascular smooth muscle cells in atherosclerosis

Improving care, outcomes for NSTEMI patients linked to higher survival rates

Regeneron announces FDA approval of EYLEA Injection for DME treatment

EMA CHMP issues positive opinion for label updates to Takeda's Vipidia, Vipdomet and Incresync

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

University of Leicester receives funding from two Masonic charities for heart study

BP variability may be ‘CV risk integrator’

IL-10 enhances positive benefits of transplanted allogenic SMCs to repair cardiac tissues after MI

Common genetic variation in gene may modify cardiovascular benefit of aspirin

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Pain control in osteoarthritis patients

Findings shed light on possible role of affective temperaments in cardiovascular morbidity

Pneumonia patients treated with azithromycin face lower risk of death, slightly increased risk of heart attack

Study demonstrates cost-effectiveness of Ottawa Model for Smoking Cessation

Counseling, medication management by pharmacist can lower hospital readmissions

Genetic variants linked to race that explains risk of death among patients taking Plavix after heart attack

Recreational football training sessions lower blood pressure and improves heart function

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News